| ATP2A3 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3 |
- Pre-NOTCH Processing in Golgi
- Reduction of cytosolic Ca++ levels
- Ion homeostasis
- Ion transport by P-type ATPases
|
|
|
| EML4 |
EMAP like 4 |
- EML4 and NUDC in mitotic spindle formation
|
|
- Non-small cell lung cancer
|
| ERBB2 |
erb-b2 receptor tyrosine kinase 2 |
- Signaling by ERBB2
- SHC1 events in ERBB2 signaling
- SHC1 events in ERBB2 signaling
- PLCG1 events in ERBB2 signaling
- PIP3 activates AKT signaling
- GRB7 events in ERBB2 signaling
- Downregulation of ERBB2:ERBB3 signaling
- GRB2 events in ERBB2 signaling
- GRB2 events in ERBB2 signaling
- PI3K events in ERBB2 signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- Sema4D induced cell migration and growth-cone collapse
- RAF/MAP kinase cascade
- ERBB2 Regulates Cell Motility
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- ERBB2 Activates PTK6 Signaling
- Downregulation of ERBB2 signaling
- TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
- Constitutive Signaling by Overexpressed ERBB2
- Drug-mediated inhibition of ERBB2 signaling
- Signaling by ERBB2 KD Mutants
- Resistance of ERBB2 KD mutants to trastuzumab
- Resistance of ERBB2 KD mutants to sapitinib
- Resistance of ERBB2 KD mutants to tesevatinib
- Resistance of ERBB2 KD mutants to neratinib
- Resistance of ERBB2 KD mutants to osimertinib
- Resistance of ERBB2 KD mutants to afatinib
- Resistance of ERBB2 KD mutants to AEE788
- Resistance of ERBB2 KD mutants to lapatinib
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
- Drug resistance in ERBB2 TMD/JMD mutants
|
- Trastuzumab
- Lapatinib
- IGN311
- Trastuzumab emtansine
- Varlitinib
- Pertuzumab
- Afatinib
- Tucatinib
- Tesevatinib
- Brigatinib
|
- Choriocarcinoma
- Pancreatic cancer
- Gastric cancer
- Bladder cancer
- Endometrial Cancer
- Ovarian cancer
- Cholangiocarcinoma
- Breast cancer
- Cervical cancer
|
| KCNJ15 |
potassium inwardly rectifying channel subfamily J member 15 |
- Activation of G protein gated Potassium channels
- Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits
|
|
|
| LGSN |
lengsin, lens protein with glutamine synthetase domain |
|
|
|
| NQO2 |
N-ribosyldihydronicotinamide:quinone reductase 2 |
- Phase I - Functionalization of compounds
|
- NADH
- Menadione
- Melatonin
- Primaquine
- Resveratrol
- Flavin adenine dinucleotide
- 10-Propargyl-5,8-Dideazafolic Acid
- Quercetin
- Tretazicar
- (3S)-3-hydroxy-1-methyl-2,3-dihydro-1H-indole-5,6-dione
- N-[2-(2-iodo-5-methoxy-1H-indol-3-yl)ethyl]acetamide
- 5,8-dimethoxy-1,4-dimethylquinolin-2(1H)-one
- 6-methoxy-9-methyl[1,3]dioxolo[4,5-h]quinolin-8(9H)-one
|
|
| PSEN1 |
presenilin 1 |
- Nuclear signaling by ERBB4
- Degradation of the extracellular matrix
- Regulated proteolysis of p75NTR
- NRIF signals cell death from the nucleus
- Activated NOTCH1 Transmits Signal to the Nucleus
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- NOTCH2 Activation and Transmission of Signal to the Nucleus
- EPH-ephrin mediated repulsion of cells
- Neutrophil degranulation
- NOTCH3 Activation and Transmission of Signal to the Nucleus
- NOTCH4 Activation and Transmission of Signal to the Nucleus
- Noncanonical activation of NOTCH3
|
|
- Acne inversa; Hidradenitis supprativa
- Frontotemporal lobar degeneration (FTLD), including: Pick disease of brain; Frontotemporal dementia (FTD); Ubiquitin-positive frontotemporal dementia (UP-FTD); Progressive supranuclear palsy type 1 (PSNP1); Inclusion body myopathy with early-onset paget disease and frontotemporal dementia (IBMPFD); Frontotemporal dementia, chromosome 3-linked (FTD3)
- Alzheimer's disease (AD)
|
| ZFAND3 |
zinc finger AN1-type containing 3 |
|
|
|